Simbrinza Pregnancy Warnings
Animal studies have shown that this drug crosses the placenta and enters into the fetal circulation to a limited extent. There are no adequate and well-controlled studies in pregnant women.
AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.
US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Use is not recommended.
AU TGA pregnancy category: B3
US FDA pregnancy category: C
Comments:
-This drug is not recommended in women of child bearing potential not using contraception.
See references